Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT ID: NCT06754891
Last Updated: 2025-01-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE1
Total Enrollment
116 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-01-31
Study Completion Date
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an open-label, single-arm Phase Ib exploratory study, divided into Cohort 1: moderate to severe active ulcerative colitis, and Cohort 2: moderate to severe active Crohn's disease. Each cohort is divided into two phases. The first phase mainly explores the safety and tolerability of three dose groups of TQH3906 (12mg, 24mg, and 32mg). Based on the findings of the first phase, the second phase of the study will be conducted to select 1-2 dose groups for preliminary efficacy confirmation in ulcerative colitis and Crohn's disease. The subjects will take TQH3906 capsules orally for 8 weeks to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of TQH3906 capsules in subjects with moderate to severe active ulcerative colitis or Crohn's disease. The study will include a screening period of up to 4 weeks, an 8-week treatment period, and a 4-week follow-up period after treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease
NCT03677648
Crohn's Disease
COMPLETED
PHASE2
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
NCT01369329
Crohn's Disease
IBD
Colitis
+1 more
COMPLETED
PHASE3
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461
Crohn's Disease
RECRUITING
PHASE2
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis
NCT07232576
Adult Patients With Moderately to Severely Active Ulcerative Colitis
NOT_YET_RECRUITING
PHASE2
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
NCT03992469
Crohn's Disease
ACTIVE_NOT_RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Inflammatory Bowel Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TQH3906 capsules
Administration of TQH3906 capsules for 8 weeks
Group Type
EXPERIMENTAL
TQH3906 capsules
Intervention Type
DRUG
TQH3906 is an allosteric inhibitor targeting kinase.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TQH3906 capsules
TQH3906 is an allosteric inhibitor targeting kinase.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18-75 years (inclusive of both 18 and 75), regardless of gender.
* Diagnosed with ulcerative colitis or Crohn's disease for ≥3 months, as assessed by histological or endoscopic examination prior to screening.
* Active moderate to severe UC or CD. .
* Subjects must have failed at least one of the following drug treatments for UC or CD or be intolerant: oral aminosalicylates, oral corticosteroids, immunosuppressants, biologics, etc.
* If subjects are using the following drugs for UC or CD at the time of screening, their treatment should be stabilized with oral aminosalicylates for at least 3 weeks before the first dose of the trial medication, or stabilized with oral systemic corticosteroids for at least 2 weeks before the first dose of the trial medication, and maintain a stable dose during the trial period.
* Subjects (including partners) are willing to voluntarily take appropriate and effective contraceptive measures from the time of screening until 3 months after the last administration of the study medication.
* Before the trial, understand in detail the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial, understand the research procedures, and voluntarily sign the informed consent form.
* Diagnosed with ulcerative colitis or Crohn's disease for ≥3 months, as assessed by histological or endoscopic examination prior to screening.
* Active moderate to severe UC or CD. .
* Subjects must have failed at least one of the following drug treatments for UC or CD or be intolerant: oral aminosalicylates, oral corticosteroids, immunosuppressants, biologics, etc.
* If subjects are using the following drugs for UC or CD at the time of screening, their treatment should be stabilized with oral aminosalicylates for at least 3 weeks before the first dose of the trial medication, or stabilized with oral systemic corticosteroids for at least 2 weeks before the first dose of the trial medication, and maintain a stable dose during the trial period.
* Subjects (including partners) are willing to voluntarily take appropriate and effective contraceptive measures from the time of screening until 3 months after the last administration of the study medication.
* Before the trial, understand in detail the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial, understand the research procedures, and voluntarily sign the informed consent form.
Exclusion Criteria
* Pregnant or breastfeeding women.
* Subjects diagnosed with indeterminate colitis, radiation colitis, or ischemic colitis.
* Have severe complications such as local stenosis, intestinal obstruction, intestinal perforation, lower gastrointestinal bleeding, intestinal cancer or tendency towards cancer, toxic megacolon; rectal colon polyps and anal diseases, etc., as assessed by the investigator, may affect the subject's efficacy and safety assessment.
* Subjects currently have a stoma, ileal pouch-anal anastomosis, fistula, and according to the physician's judgment, may require surgery or drug intervention within 12 weeks of entering the study, or may require ileostomy or colostomy.
* Subjects have had a large segment of the small intestine resected (\>100cm) or have been diagnosed with short bowel syndrome, or subjects require total parenteral nutrition.
* Subjects have a recorded positive test for Clostridium difficile toxin (C. difficile) in stool or positive polymerase chain reaction (PCR) test. If the result is positive, subjects may be re-screened after appropriate treatment and re-tested no earlier than 7 days after the end of treatment.
* Abnormal serum virology during the screening period: a) Active hepatitis, or positive for Hepatitis B surface antigen (HBsAg) and positive for hepatitis B virus (HBV)-DNA, or positive for Hepatitis B core antibody (HBcAb) and positive for HBV-DNA, or positive for hepatitis B virus (HCV) antibodies and positive for HCV-RNA; b) Positive for HIV antibodies during the screening period, or history of HIV infection; c) Positive for Treponema pallidum antibodies and positive for non-treponemal serologic tests (RPR or TRUST) during the screening period.
* History of active tuberculosis during the screening period or latent tuberculosis infection (defined as enzyme-linked immunospot assay (T-SPOT) positive without clinical manifestations). (Note: Patients with latent tuberculosis infection may be re-screened after starting preventive treatment for one month according to the guidelines. To continue participating in the study, patients must agree to complete the preventive treatment plan during the study period, but rifampin treatment should be avoided.)
* History of severe herpes zoster or herpes simplex infection, including but not limited to herpes encephalitis, disseminated herpes simplex, and generalized herpes zoster.
* History of severe bacterial, fungal, or viral infections within 2 months before the first dose requiring hospitalization and intravenous antibiotic or antiviral treatment.
* Received live vaccines within 4 weeks before the first dose or plan to receive live vaccines during the study period.
* Clinically significant infections during the screening period, including but not limited to upper respiratory tract infections, lower respiratory tract infections, herpes simplex, herpes zoster, requiring antibiotic or antiviral treatment.
* Subjects with any major illness or unstable clinical condition (such as kidney, liver, blood, gastrointestinal, endocrine, lung, mental, neurological, immune, or local active infection/infectious diseases), as determined by the investigator, are not suitable for participating in this study.
* Abnormal laboratory tests during the screening period: a) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times the upper limit of normal (ULN); b) Hemoglobin \<90g/L; c) White blood cell count \<3.0×109/L; d) Neutrophil count \<1.0×109/L; e) Lymphocyte count \<0.5×109/L; f) Platelet count \<100×109/L; g) Total bilirubin \>2 times ULN; h) Other significant laboratory test abnormalities that the investigator considers the subject unsuitable for participation in this study.
* Subjects with poorly controlled diabetes or diabetes with significant complications (such as retinopathy or nephropathy).
* History of malignant tumors (including in situ carcinoma) and lymphoproliferative diseases within 5 years before the first dose.
* Received any marketed or investigational biologics within 8 weeks before the first dose or 5 half-lives (whichever is longer).
* Received small molecule drugs such as Upadacitinib, Ozanimod, or other marketed or investigational drugs within 4 weeks or 5 half-lives (whichever is longer) before the first dose.
* Received fecal microbiota transplantation, cyclosporine, tacrolimus, mycophenolate mofetil, thalidomide, or other drugs within 4 weeks before the first dose.
* Received any other investigational drugs within 1 month or 5 half-lives (whichever is longer) before the first dose.
* Underwent surgical procedures within 4 weeks before the first dose or plan to undergo surgical procedures during the study period.
* Received immunoglobulins or blood products within 4 weeks before the first dose.
* Used potent CYP450 inducers (such as rifampin, phenobarbital, carbamazepine, phenytoin sodium, etc.) within 4 weeks before the first dose.
* Used local treatments (enemas or suppositories), intravenous steroids, azathioprine or 6-mercaptopurine, anti-UC or CD Chinese medicine, anti-infective drugs, or anti-diarrheal drugs within 2 weeks before the first dose.
* Subjects receiving methotrexate treatment must not have received methotrexate treatment for the current course within at least 42 days before screening, or stable-dose methotrexate treatment within at least 28 days before the first dose.
* Received nonsteroidal anti-inflammatory drug (NSAID) treatment within 1 week before the first dose (except for topical NSAIDs and low-dose aspirin for cardiovascular protection).
* Subjects who have undergone organ transplantation and require ongoing immunosuppressive treatment.
* Allergic to any known components of TQH3906, or with any history of severe drug allergies.
* History of drug abuse or positive urine drug screening.
* Any other reasonable medical, psychiatric, or social reasons that the investigator considers the subject unable to participate in this study.
* Subjects diagnosed with indeterminate colitis, radiation colitis, or ischemic colitis.
* Have severe complications such as local stenosis, intestinal obstruction, intestinal perforation, lower gastrointestinal bleeding, intestinal cancer or tendency towards cancer, toxic megacolon; rectal colon polyps and anal diseases, etc., as assessed by the investigator, may affect the subject's efficacy and safety assessment.
* Subjects currently have a stoma, ileal pouch-anal anastomosis, fistula, and according to the physician's judgment, may require surgery or drug intervention within 12 weeks of entering the study, or may require ileostomy or colostomy.
* Subjects have had a large segment of the small intestine resected (\>100cm) or have been diagnosed with short bowel syndrome, or subjects require total parenteral nutrition.
* Subjects have a recorded positive test for Clostridium difficile toxin (C. difficile) in stool or positive polymerase chain reaction (PCR) test. If the result is positive, subjects may be re-screened after appropriate treatment and re-tested no earlier than 7 days after the end of treatment.
* Abnormal serum virology during the screening period: a) Active hepatitis, or positive for Hepatitis B surface antigen (HBsAg) and positive for hepatitis B virus (HBV)-DNA, or positive for Hepatitis B core antibody (HBcAb) and positive for HBV-DNA, or positive for hepatitis B virus (HCV) antibodies and positive for HCV-RNA; b) Positive for HIV antibodies during the screening period, or history of HIV infection; c) Positive for Treponema pallidum antibodies and positive for non-treponemal serologic tests (RPR or TRUST) during the screening period.
* History of active tuberculosis during the screening period or latent tuberculosis infection (defined as enzyme-linked immunospot assay (T-SPOT) positive without clinical manifestations). (Note: Patients with latent tuberculosis infection may be re-screened after starting preventive treatment for one month according to the guidelines. To continue participating in the study, patients must agree to complete the preventive treatment plan during the study period, but rifampin treatment should be avoided.)
* History of severe herpes zoster or herpes simplex infection, including but not limited to herpes encephalitis, disseminated herpes simplex, and generalized herpes zoster.
* History of severe bacterial, fungal, or viral infections within 2 months before the first dose requiring hospitalization and intravenous antibiotic or antiviral treatment.
* Received live vaccines within 4 weeks before the first dose or plan to receive live vaccines during the study period.
* Clinically significant infections during the screening period, including but not limited to upper respiratory tract infections, lower respiratory tract infections, herpes simplex, herpes zoster, requiring antibiotic or antiviral treatment.
* Subjects with any major illness or unstable clinical condition (such as kidney, liver, blood, gastrointestinal, endocrine, lung, mental, neurological, immune, or local active infection/infectious diseases), as determined by the investigator, are not suitable for participating in this study.
* Abnormal laboratory tests during the screening period: a) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times the upper limit of normal (ULN); b) Hemoglobin \<90g/L; c) White blood cell count \<3.0×109/L; d) Neutrophil count \<1.0×109/L; e) Lymphocyte count \<0.5×109/L; f) Platelet count \<100×109/L; g) Total bilirubin \>2 times ULN; h) Other significant laboratory test abnormalities that the investigator considers the subject unsuitable for participation in this study.
* Subjects with poorly controlled diabetes or diabetes with significant complications (such as retinopathy or nephropathy).
* History of malignant tumors (including in situ carcinoma) and lymphoproliferative diseases within 5 years before the first dose.
* Received any marketed or investigational biologics within 8 weeks before the first dose or 5 half-lives (whichever is longer).
* Received small molecule drugs such as Upadacitinib, Ozanimod, or other marketed or investigational drugs within 4 weeks or 5 half-lives (whichever is longer) before the first dose.
* Received fecal microbiota transplantation, cyclosporine, tacrolimus, mycophenolate mofetil, thalidomide, or other drugs within 4 weeks before the first dose.
* Received any other investigational drugs within 1 month or 5 half-lives (whichever is longer) before the first dose.
* Underwent surgical procedures within 4 weeks before the first dose or plan to undergo surgical procedures during the study period.
* Received immunoglobulins or blood products within 4 weeks before the first dose.
* Used potent CYP450 inducers (such as rifampin, phenobarbital, carbamazepine, phenytoin sodium, etc.) within 4 weeks before the first dose.
* Used local treatments (enemas or suppositories), intravenous steroids, azathioprine or 6-mercaptopurine, anti-UC or CD Chinese medicine, anti-infective drugs, or anti-diarrheal drugs within 2 weeks before the first dose.
* Subjects receiving methotrexate treatment must not have received methotrexate treatment for the current course within at least 42 days before screening, or stable-dose methotrexate treatment within at least 28 days before the first dose.
* Received nonsteroidal anti-inflammatory drug (NSAID) treatment within 1 week before the first dose (except for topical NSAIDs and low-dose aspirin for cardiovascular protection).
* Subjects who have undergone organ transplantation and require ongoing immunosuppressive treatment.
* Allergic to any known components of TQH3906, or with any history of severe drug allergies.
* History of drug abuse or positive urine drug screening.
* Any other reasonable medical, psychiatric, or social reasons that the investigator considers the subject unable to participate in this study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affilliated Hospital of Bengbu Medical University
Bengbu, Anhui, China
Site Status
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China
Site Status
First affiliated hospital of guangzhou medical university
Guangzhou, Guangdong, China
Site Status
Luoyang First People's Hospital
Luoyang, Henan, China
Site Status
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Site Status
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Site Status
Union Hosiptal, Tongji Medical College, Huazhong University of Science And Technolocy
Wuhan, Hubei, China
Site Status
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Site Status
Xiangya Hospital of Central South University
Changsha, Hunan, China
Site Status
The First Affiliated Hospital Of University Of South China
Hengyang, Hunan, China
Site Status
The first hospital of Jilin University
Changchun, Jilin, China
Site Status
Meihekou Central Hospital
Meihekou, Jilin, China
Site Status
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Site Status
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China
Site Status
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China
Site Status
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TQH3906-Ib-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
NCT02877134
COMPLETED
PHASE2
Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease
NCT02015793
COMPLETED
PHASE2
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
NCT01369342
COMPLETED
PHASE3
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT03650413
TERMINATED
PHASE2
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
NCT04877990
COMPLETED
PHASE2
Efficacy and Safety of TD-1473 in Crohn's Disease
NCT03635112
TERMINATED
PHASE2
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
NCT02378688
COMPLETED
PHASE2
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
NCT03599622
TERMINATED
PHASE2
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801
RECRUITING
PHASE3
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
NCT01277666
COMPLETED
PHASE3
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440372
TERMINATED
PHASE3
Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease
NCT06780683
RECRUITING
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
NCT03478956
TERMINATED
PHASE1
Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease
NCT06925594
RECRUITING
PHASE3
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
NCT00160524
COMPLETED
PHASE3
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
NCT01203631
COMPLETED
PHASE2
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
NCT00101946
COMPLETED
PHASE2
A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.
NCT03675477
COMPLETED
PHASE2
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897
RECRUITING
PHASE3
IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study
NCT06573944
RECRUITING
A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis
NCT01453491
COMPLETED
PHASE1
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
NCT00805766
COMPLETED
PHASE3
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440385
COMPLETED
PHASE3
A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis
NCT01658605
WITHDRAWN
PHASE2
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
NCT04151225
WITHDRAWN
PHASE2